Brief: Maxcyte Advances Phase I Clinical Trial Of Lead Carma Mrna-Based Cell Therapy To Third Cohort Of Patients
24/10/2019 08:17
Oct 24 (Reuters) - MaxCyte Inc MXCT.L :
* MAXCYTE, INC. MAXCYTE, INC. - MXCR - MAXCYTE ADVANCES
PHASE I
CLINICAL TRIAL
* MAXCYTE INC - MAXCYTE ADVANCES PHASE I CLINICAL TRIAL OF
LEAD
CARMA™ MRNA-BASED CELL THERAPY TO THIRD COHORT OF PATIENTS
Source text for Eikon: ID:nRSX9395Qa
Further company coverage: MXCT.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics